TD Cowen analyst Jonna Kim raised the firm’s price target on Hims & Hers to $28 from $25 and keeps a Buy rating on the shares. The firm said HIMS has ample opportunities to grow weight loss as a specialty even after GLP-1s are off the shortage list, personalization is resonating with patients underpinning robust core business growth, and a path to margin expansion as the platform scales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Hims & Hers price target raised to $27 from $23 at Deutsche Bank
- Hims & Hers price target raised to $32 from $28 at Seaport Research
- Hims & Hers price target raised to $21 from $18 at Piper Sandler
- Hims & Hers price target raised to $28 from $24 at Canaccord
- Hims & Hers Health Reports Strong Q3 2024 Growth